Please ensure Javascript is enabled for purposes of website accessibility
홈 > 제품 > 어세이 키트 > ADA 어세이 키트

Anifrolumab ELISA Kit (DB823018)

Anifrolumab ELISA Kit
Anifrolumab ELISA Kit
가격(USD):
사양:
  • 96T
수량:
문의하기
  • 개요

  • 이미지

  • 참고 문헌

  • 데이터시트

  • SDS

개요
카탈로그 번호DB823018
설명
Anifrolumab ELISA Kit (DB823018) — Quantitative competitive ELISA for Anifrolumab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Sensitivity: 0.156 μg/ml.
Highlights
  • ●Competitive Format — High specificity, reliable quantification.
  • ●High Sensitivity — Optimized for low-abundance target detection.
  • ●Ready-to-Use — Complete kit with pre-coated plates included.
샘플 유형Plasma, Serum
민감도69.49 ng/ml
범위93.75-6,000 ng/ml
등록번호 P17181
응용 분야 ELISA
검출 방법 Colorimetric
분석 유형 Quantitative
회수율 80-120%
배송 2-8 ℃
안정성 및 저장 The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
사양

Anifrolumab

대체 이름MDX-1333, MEDI-546, 1326232-46-5
배경

Interferon alpha/beta receptor 1 (Anifrolumab) is a ~63 kDa protein. Together with IFNAR2, forms the heterodimeric receptor for type I interferons (including interferons alpha, beta, epsilon, omega and kappa). Type I interferon binding activates the JAK-STAT signaling cascade, resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon response. Mechanistically, type I interferon-binding brings the IFNAR1 and IFNAR2 subunits into close proximity with one another, driving their associated Janus kinases (JAKs) (TYK2 bound to IFNAR1 and JAK1 bound to IFNAR2) to cross-phosphorylate one another. The activated kinases phosphorylate specific tyrosine residues on the intracellular domains of IFNAR1 and IFNAR2, forming docking sites for the STAT transcription factors. STAT proteins are then phosphorylated by the JAKs, promoting their translocation into the nucleus to regulate expression of interferon-regulated genes.

1. Russell-Harde, D. et al. (1999) Biochemical and biophysical research communications 255, 539-44. PMID: 10049744
2. Kumar, KG. et al. (2003) The EMBO journal 22, 5480-90. PMID: 14532120
3. Kumar, KG. et al. (2004) The Journal of biological chemistry 279, 46614-20. PMID: 15337770
4. Uzé, G. et al. (1990) Cell 60, 225-34. PMID: 2153461
5. Thomas, C. et al. (2011) Cell 146, 621-32. PMID: 21854986
6. Zheng, H. et al. (2013) Cell reports 5, 180-93. PMID: 24075985
7. Hernandez, N. et al. (2019) The Journal of experimental medicine 216, 2057-2070. PMID: 31270247
8. Gothe, F. et al. (2022) Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 74, 136-139. PMID: 33252644
9. Bastard, P. et al. (2022) The Journal of experimental medicine 219. PMID: 35442418
10. Abramovich, C. et al. (1994) The EMBO journal 13, 5871-7. PMID: 7813427
참고사항 For Research Use Only.
이미지
  • Anifrolumab ELISA Kit

    Standard Curve

    Standard Curve of Anifrolumab ELISA Kit

참고 문헌
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
추천

문의하기 맞춤형 견적, 대량 주문 및 기타 문의 사항은

메일: [email protected]

배급사 목록